AI Article Synopsis
- The development of immune checkpoint inhibitors has significantly improved response and survival rates for many cancers, marking a new era in tumor immunotherapy.
- Despite their success, resistance to these treatments limits the number of patients who benefit over the long term, and immune-related adverse events (irAEs) pose additional challenges.
- The text reviews the mechanisms of action of immune checkpoint inhibitors, explores various types of irAEs and their potential causes, and discusses strategies for prevention and therapeutic interventions to address these complications.
Article Abstract
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247998 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1167975 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!